Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma
Autore:
Chua, D; Huang, J; Zheng, BJ; Lau, SY; Luk, W; Kwong, DLW; Sham, JST; Moss, D; Yuen, KY; Im, SWK; Ng, MH;
Indirizzi:
Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China UnivHong Kong Hong Kong Hong Kong Peoples R China Kong, Peoples R China Univ Hong Kong, Dept Radiat Oncol, Hong Kong, Hong Kong, Peoples R China Univ Hong Kong Hong Kong Hong Kong Peoples R China Kong, Peoples R China Queensland Inst Med Res, Brisbane, Qld 4006, Australia Queensland Inst MedRes Brisbane Qld Australia 4006 , Qld 4006, Australia
Titolo Testata:
INTERNATIONAL JOURNAL OF CANCER
fascicolo: 1, volume: 94, anno: 2001,
pagine: 73 - 80
SICI:
0020-7136(20011001)94:1<73:ATOAEV>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; ACTIVE EBV INFECTION; PERIPHERAL-BLOOD; LYMPHOPROLIFERATIVE DISORDERS; CELLULAR-IMMUNITY; NUCLEAR ANTIGEN-1; LYMPHOCYTES; EXPRESSION; GENE; IGA;
Keywords:
nasopharyngeal carcinoma; Epstein-Barr virus; adoptive immune transfer; cytotoxic T cell; peripheral blood monocyte;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
53
Recensione:
Indirizzi per estratti:
Indirizzo: Ng, MH Univ Hong Kong, Dept Microbiol, Univ Pathol Bldg,Queen Mary Hosp Cpd,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China Univ Hong Kong Univ Pathol Bldg,Queen Mary Hosp Cpd,Pokfulam Rd Hong Kong Hong Kong Peoples R China
Citazione:
D. Chua et al., "Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma", INT J CANC, 94(1), 2001, pp. 73-80

Abstract

Tumor cells from NPC patients are regularly and latently infected with EBV. To examine whether the virus serves as target for immune intervention of the cancer, we determined levels of EBV-specific CTLp in peripheral blood from NPC patients, long-term survivors of the cancer and healthy subjects. CTLp levels of test subjects varied between 3-3,000/10(6) PBMCs. The plasma EBV burden increased when the CTLp level fell below 150, whereas the EBV burden of PBMCs was not correlated with CTLp level. Compared with healthy carriers, CTLp levels of patients were lower and varied over a wider range, between 3-1,500/10(6) PBMCs. The quantitative immune deficit was probably attributed to the tumor because, first, CTLp in survivors was restored to levels similar to those in healthy carriers after the tumor had been successfully treated. Second, the CTLp level changed as disease progressed, being lower in local disease, increased in locoregional disease and decreased again when the tumor metastasized. Based on these findings, 4 patients with advanced disease were infused with 5 x 10(7)-3 x 10(8) autologous EBV CTLs. The treatment was safe and unaccompanied by inflammatory or other complications, but whether it improved tumor control could not be discerned from the large tumor bulk. Nevertheless, the treatment regularly increased CTLp levels of patients, maintained it at higher levels for protracted periods and, in 3 patients, restored host surveillance of EBV replication, reducing the plasma EBV burden. Taken together, these results provided a rationale to further explore EBV as a target of immune intervention of NPC. (C) 2001 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/09/20 alle ore 22:43:15